Emerging Trends in the Management of Hepatitis C Virus Infection: Best Practices for Achieving Sustained Virologic Responses
This program applies emerging evidence and current practice guidelines to address the contemporary challenges in achieving sustained virologic responses (SVR) in all patients with hepatitis C virus (HCV), including those who are difficult to treat. Case studies demonstrating new approaches to managing treatment naive and direct acting antiviral (DAA) experienced patients with resistant HCV infection are discussed. The program emphasizes the importance of collaboration among healthcare professionals in order to achieve optimal patient outcomes.
Agenda
Welcome and Introductions
Jason J. Schafer, Pharm.D., M.P.H., BCPS, AAHIVP
Strategies for Achieving SVR in DAA Treatment-Naive HCV Infected Patients
William R. Short, M.D., M.P.H.
Emerging Approaches to Managing HCV Infection in Patients with DAA Treatment Experience
Jason J. Schafer, Pharm.D., M.P.H., BCPS, AAHIVP
Audience Questions
Learning Objectives
- Discuss trends in the epidemiology of HCV infection and the corresponding recommendations for screening and diagnosis.
- Apply study data and recommendations from current guidelines for managing treatment naive HCV infected patients, including those who are harder to treat.
- Evaluate current and emerging treatment options for patients who have had DAA treatment failure.
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of patients with hepatitis C virus infection.
Format
This online activity consists of slide presentations, active learning, an assessment, and evaluation. View the system requirements.
Disclosure Statement
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individual below has disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
William R. Short, MD, M.P.H., AAHIVS
- Gilead Sciences: consultant
- Janssen Pharmaceuticals: speaker bureau
Claim CE within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to complete the assessment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-0000-17-439-H01-P
Release Date: March 1, 2018
Expiration Date: May 21, 2019
Activity Type: Application-based
CE Credits: 1.5, no partial credit for pharmacists
Activity Fee: Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Jason J. Schafer, Pharm.D., M.P.H., BCPS, AAHIVP, 
William R. Short, M.D., M.P.H., AAHIVS